The legacy of Viagra and its originator, copyright, presents a fascinating picture for cautious investors. While the iconic drug initially produced enormous earnings, its exclusivity has ended, leading to competing alternatives flooding the market . This erosion in value presents a substantial challenge for copyright and any fund considering a heav